LRRK2 and Parkinson disease: S-181 shows a propensity to increase GCase activity in human dopaminergic neurons harboring PD mutations (GBA1, LRRK2, and PARKIN), allowing for the restoration of lysosomal function, and reductions in the accumulation of oxidized dopamine and α-syn [118].